{"uid":"cap_k3cFCeS_X3tQWtnDKqHAk","slug":"armstrong-2018-prevail-cox-linear-predictor-for-mcrpc-overall-survival-844b22f4","name":"Armstrong 2018 PREVAIL Cox Linear Predictor for mCRPC Overall Survival","description":"Armstrong 2018 PREVAIL Cox linear predictor for overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer from albumin, ALP versus ULN, bone metastases under 10, hemoglobin, LDH versus ULN, NLR under 2.5, pain 0-1, liver metastases, ln(PSA), months from diagnosis, and enzalutamide versus placebo. Table 1 HRs as ln(HR). Not a 1-/2-/3-year OS percent (no published S0). magent does not read bone scans. Not a dose or treatment order.","url":"https://api.magentlab.com/api/calc/prevail","method":"GET","headers":{},"bodySchema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"headers":{"type":"object","additionalProperties":{"type":"string"}},"queryParams":{"type":"object","required":["albumin_g_dl","alp_below_uln","bone_mets_lt_10","hemoglobin_g_dl","ldh_below_uln","nlr_lt_2_5","pain_0_to_1","no_liver_metastases","psa_ng_ml","months_since_diagnosis","treatment_enzalutamide"],"properties":{"psa_ng_ml":{"type":"number","description":"Baseline PSA in ng/mL (0.1-10000). Table 1: continuous log_e PSA, HR 1.23 per ln(ng/mL). magent does not assay PSA."},"nlr_lt_2_5":{"type":"boolean","description":"Neutrophil-to-lymphocyte ratio <2.5 as assigned by the caller (true or false). Table 1: true (<2.5 versus ≥2.5) has HR 0.69. magent does not compute NLR from counts."},"pain_0_to_1":{"type":"boolean","description":"Pain score 0-1 versus ≥2 on the paper's linear scale, as assigned by the caller (true or false). Table 1: true (0-1 versus ≥2) has HR 0.77. magent does not assign pain scores."},"albumin_g_dl":{"type":"number","description":"Serum albumin in g/dL (1.0-6.5). Armstrong 2018 Table 1: continuous, HR 0.71 per g/dL. magent does not assay albumin."},"alp_below_uln":{"type":"boolean","description":"Alkaline phosphatase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus ≥ULN) has HR 0.79. magent does not assay ALP or apply ULN."},"ldh_below_uln":{"type":"boolean","description":"Lactate dehydrogenase below the institutional ULN as assigned by the caller (true or false). Table 1: true (<ULN versus ≥1×ULN) has HR 0.67. magent does not assay LDH or apply ULN."},"bone_mets_lt_10":{"type":"boolean","description":"Fewer than 10 bone metastases as assigned by the caller (true or false). Table 1: true (<10 versus ≥10) has HR 0.68. magent does not read bone scans."},"hemoglobin_g_dl":{"type":"number","description":"Hemoglobin in g/dL (3.0-22.0). Table 1: continuous, HR 0.85 per g/dL. magent does not assay hemoglobin."},"no_liver_metastases":{"type":"boolean","description":"No liver metastases as assigned by the caller (true or false). Table 1 pattern of spread: true (no liver metastases versus any liver metastases) has HR 0.49. magent does not read imaging."},"months_since_diagnosis":{"type":"number","description":"Time from diagnosis to randomization in months (0-720). Table 1: continuous, HR 0.997 per month. magent does not date the interval."},"treatment_enzalutamide":{"type":"boolean","description":"true if the PREVAIL treatment term is enzalutamide, false if placebo. Table 1: true (enzalutamide versus placebo) has HR 0.68. Not a dose or treatment order."}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"example":{"type":"object"}}}}},"responseSchema":null,"example":null,"exampleRequest":null,"tags":["x402"],"displayCostAmount":"0.005","displayCostAsset":"USDC","priceDynamic":false,"priceHint":null,"priceStatus":"priced","priceSource":"probe","requiresHandshake":false,"reviewCount":0,"rating":{"score":"0.00","successRate":"0.00","reviews":0,"stars":null,"state":"unrated"},"availabilityStatus":"unknown","priceObserved":null,"sessionDeposit":null,"pricing":{"kind":"static","summary":"$0.005/call","primary":{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"},"accepted":[{"kind":"static","protocol":"x402","network":"base","amountUsd":"0.005","per":"call","confidence":"exact"}]},"paymentMethods":[{"uid":"pm_3pPypQGQHs8UsqdLFJx0U","protocol":"x402","methodType":"crypto","chain":"base","mode":"charge","costAmount":"0.005","costPer":"request","priority":0,"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","unit":"request","depositMicros":null,"planRef":null}],"brandName":null,"brandSlug":null,"brandBaseUrl":null,"brandDocsUrl":null,"whatItDoes":"Computes the Armstrong 2018 PREVAIL trial Cox linear predictor score for overall survival in chemotherapy-naïve metastatic castration-resistant prostate cancer given 11 clinical variables","exampleAgentPrompt":"Compute the Armstrong 2018 PREVAIL Cox linear predictor for a chemotherapy-naïve mCRPC patient: albumin 3.8 g/dL, ALP below ULN, fewer than 10 bone mets, hemoglobin 12.1 g/dL, LDH below ULN, NLR less than 2.5, pain score 0–1, no liver metastases, PSA 45 ng/mL, 18 months since diagnosis, on enzalutamide.","exampleUseCases":[{"title":"Oncology trial eligibility risk stratification","prompt":"I need the PREVAIL Cox predictor score for a mCRPC patient being considered for a trial: albumin 4.0 g/dL, ALP above ULN, 12 or more bone mets, hemoglobin 11.5 g/dL, LDH above ULN, NLR 3.1 so not less than 2.5, pain score 3 so not 0-1, no liver mets, PSA 120 ng/mL, 24 months from diagnosis, and they'd be on placebo."},{"title":"Enzalutamide versus placebo OS risk comparison","prompt":"Run the Armstrong 2018 PREVAIL linear predictor twice for my patient — once assuming enzalutamide and once assuming placebo — so I can compare the ln(HR) difference. Albumin 3.5 g/dL, ALP below ULN, fewer than 10 bone mets, hemoglobin 13.0 g/dL, LDH below ULN, NLR less than 2.5, pain 0-1, no liver mets, PSA 22 ng/mL, 30 months since diagnosis."},{"title":"High-risk mCRPC prognostic scoring","prompt":"Score this high-risk chemotherapy-naïve mCRPC patient using the PREVAIL Cox model: albumin 2.9 g/dL, ALP above ULN, 15 bone mets so above 10, hemoglobin 10.2 g/dL, LDH above ULN, NLR 4.0 so not less than 2.5, pain score 5 so not 0-1, liver metastases present, PSA 850 ng/mL, 8 months since diagnosis, treatment enzalutamide."}],"resultDescription":"Returns the Armstrong 2018 PREVAIL Cox linear predictor value expressed as ln(HR), computed from the 11 caller-supplied clinical variables using the Table 1 hazard ratios. Does not return a 1-, 2-, or 3-year OS percentage (no published S0 baseline survival function is applied). This is a continuous risk score, not a treatment recommendation.","failureModes":["Missing required query parameters returns a 400 error","PSA value outside the 0.1–10000 ng/mL range may be rejected or yield out-of-range results","Boolean flags (NLR, pain, ALP, LDH, bone mets, liver mets, treatment) must be true/false; string or numeric values will fail validation","albumin or hemoglobin outside physiological bounds may cause errors","Payment not included or insufficient USDC will result in a 402 Payment Required response"],"whenToPreferThis":"Use this endpoint when you need the validated Armstrong 2018 PREVAIL trial Cox linear predictor for chemotherapy-naïve mCRPC patients and have all 11 clinical variables available as caller-assigned values. Prefer this over generic survival calculators when you specifically want the PREVAIL trial-derived hazard ratio coefficients from Table 1. Do not use it to obtain OS percentages, to read bone scans, to assay lab values, or to assign pain/NLR scores — those must be provided by the caller.","instructions":null,"reviewSummary":null,"reviewSummaryHighlights":null,"reviewSummaryConcerns":null,"reviewSummaryGeneratedAt":null,"activationCount":0,"lastUsedAt":null,"lastSuccessfullyRanAt":null,"lastHealthCheckAt":"2026-09-14T06:45:01.828Z","isFirstParty":false}